meta|Evidence - COVID-19
click on circles to display study description...
zinc (n=15) vs. placebo (n=18)
- high risk of bias
High-dose Zinc HDIVZn
Zinc Chloride (ZnCl2) diluted in 250 mL of normal saline and infused via peripheral intravenous access over 3 hrs at a dose of 0.5 mg/kg/d (elemental zinc concentration 0.24 mg/kg/d), once daily, for a maximum of 7 days, or until hospital discharge or death.
Placebo
Saline placebo.
COVID 19 hospitalized
Consenting adult patients adult male or female, age ≥18years old, laboratory-confirmedSARS-CoV-2 infection as determined by PCR, hospitalised with an illness of any duration with evidence of pneumonia and severe disease, critical disease or multisystem organ dysfunction at baseline, ability to provide informed consent signed by study patient or legally acceptable representative, willingness and ability to comply with study-related procedures/assessments, have an oxygen saturation (SaO2) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (PaO2) to the fraction of inspired oxygen(FiO2) (PaO2: FiO2) at or below 300 mg Hg, no chronic kidney disease (CKD) defined by stage II or higher using the Kidney Disease Improving Global Outcomes classification.
Double-blind.
Phase IIa. The investigators, study coordinators, treating physicians, bedside nurses and patients/family remained blinded to the allocated studysolution.
The study did not reach its target enrolment. Consequently, the primary outcome of whether HDIVZn reduced thelevel of oxygenation in non-ventilated or improved the PaO2/FiO2 ratio in the four ventilated patients and other clinical efficacy outcomes could not be assessed.
powered by vis.js Network